What's new? Log in Free sign up

Sanofi (SNY)

Company Profile

Company profile

Ticker

SNY, SNYNF

Exchange

Website

CEO

Mr. Paul Hudson

Incorporated

Location

Fiscal year end

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Alabama Power • Mississippi Power • Teva Pharmaceutical Industries Limited • Entergy Arkansas • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb ...

Former names

SANOFI SYNTHELABO SA, SANOFI-AVENTIS

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

IRS number

133529324

SNY stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Current report (foreign)

Availability of the profit and loss information of Sanofi excluding Opella

Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma

Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis

Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI

Q3 sales growth of 15.7% at CER and business EPS(1) of €2.86

Sanofi and Orano join forces to develop next-generation radioligand medicines

Current report (foreign)

Dupixent approved in China as the first-ever biologic medicine for patients with COPD

Global regulatory submissions will begin in H2 2024

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

Annual report of employee stock purchases

Annual report of employee stock purchases

Inhibrx Biosciences, Inc.

MeiraGTx Holdings plc

Annual report of employee stock purchases

Annual report of employee stock purchases

Financial summary

Financial statements Chart SNY financial data

Quarter (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Sanofi earnings reports.

Institutional ownership, Q3 2024

SNY institutional ownership history Ownership history

11.2% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	730	712	+2.5%
Opened positions	87	87	–
Closed positions	69	70	-1.4%
Increased positions	289	317	-8.8%
Reduced positions	224	184	+21.7%

13F shares	Current	Prev Q	Change
Total value	15.45 tn	12.77 tn	+21.0%
Total shares	283.11 mm	271.45 mm	+4.3%
Total puts	1.57 mm	1.31 mm	+19.7%
Total calls	1.97 mm	2.58 mm	-23.5%
Total put/call ratio	0.8	0.5	+56.4%

Largest owners	Shares	Value	Change
Dodge & Cox	76.30 mm	$4.40 tn	-1.1%
MS Morgan Stanley	17.78 mm	$1.02 tn	+20.6%
Fisher Asset Management	13.36 mm	$769.89 bn	-1.8%
IVZ Invesco	11.65 mm	$671.42 bn	+10.8%
BAC Bank of America	11.58 mm	$667.10 bn	+3.3%
BLK BlackRock	10.34 mm	$595.80 bn	NEW
BK The Bank of New York Mellon Corporation	9.31 mm	$536.68 bn	+8.4%
BEN Franklin Resources	8.96 mm	$492.01 bn	+197.5%
FMR	8.62 mm	$496.63 bn	-43.4%
Barrow Hanley Mewhinney & Strauss	7.84 mm	$451.69 bn	+31.9%

Largest transactions	Shares	Bought/sold	Change
BLK BlackRock	10.34 mm	+10.34 mm	NEW
BLK BlackRock	0.00	-10.11 mm	EXIT
FMR	8.62 mm	-6.60 mm	-43.4%
BEN Franklin Resources	8.96 mm	+5.95 mm	+197.5%
T. Rowe Price	5.75 mm	+3.89 mm	+209.0%
Mondrian Investment Partners	0.00	-3.51 mm	EXIT
MS Morgan Stanley	17.78 mm	+3.04 mm	+20.6%
Barrow Hanley Mewhinney & Strauss	7.84 mm	+1.89 mm	+31.9%
Jennison Associates	1.90 mm	+1.72 mm	+938.0%
Thrivent Financial For Lutherans	1.43 mm	+1.42 mm	+28890.2%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

Sanofi Launches Phase 3 Trials For PCV21 And Strengthens Partnership With SK Bioscience On Next-Generation Pneumococcal Conjugate Vaccines

Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccinesPneumococcal disease remains a major global health challenge despite the

Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio?

The top-performing stocks last week were TEVA, KVYO, DRI, DOCS, BIRK, JBL, NBIX, GME, RDY, and LI. Did you have any of them in your portfolio?

Cytokinetics Announces Sanofi's Acquisition Of Aficamten Rights For HCM Treatment In Greater China

In 2020, CORXEL (formerly Ji Xing) acquired the rights to develop and commercialize aficamten in Greater China (including the Chinese mainland, Hong Kong SAR and Macau SAR, and Taiwan) from Cytokinetics in accordance

CA Governor Newsom Proclaimed State Of Emergency To Further Enhance State's Preparedness And Accelerate The Bird Flu Cross-Agency Response Efforts

Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases

Press releases

From Benzinga Pro

Beyfortus® immunization to protect infants from RSV has begun

Six out of 10 infants and newborns in Canada will have access to the protective antibody Beyfortus® for the first time this seasonAccess to Beyfortus® includes infants in remote communities most impacted by

FLUBLOK® (Influenza Vaccine) US label updated with one of Sanofi's largest flu vaccine safety studies in pregnant individuals

US FLUBLOK label1 updated to incorporate new safety study in pregnant individualsNew safety data involving more than 48,000 pregnant individuals published in American Journal of Obstetrics and Gynecology (AJOG) Global

Sanofi commits $18 million to Howard University College of Medicine, Meharry Medical College, and Morehouse School of Medicine to increase diversity in clinical studies

BRIDGEWATER, N.J., Oct. 16, 2024 /PRNewswire/ -- Sanofi announced today it will contribute $18 million to three Historically Black Medical Schools to help the institutions work to increase diversity in clinical studies.

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.